Welcome to our dedicated page for Immuneering news (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering stock.
Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage oncology company developing Deep Cyclic Inhibitors, with a lead focus on atebimetinib, an oral, once-daily MEK inhibitor for MAPK pathway-driven cancers such as pancreatic cancer. This news page aggregates company announcements, clinical data updates, financing news, and other disclosures that Immuneering releases through press statements and regulatory filings.
Readers can find detailed coverage of Immuneering’s clinical trial progress, including Phase 2a data for first-line pancreatic cancer patients treated with atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP). The company has reported updated overall survival, progression-free survival, response rates, and safety findings from a cohort of 34 patients, as well as case studies of patients treated with atebimetinib plus FOLFIRINOX. Immuneering also provides timelines for anticipated milestones such as additional survival data readouts and the planned initiation of a global Phase 3 registrational trial in metastatic pancreatic cancer.
In addition to clinical results, Immuneering’s news flow includes corporate and financial updates such as quarterly financial results, underwritten public offerings of Class A common stock, private placements with institutional investors, and guidance on expected cash runway. Announcements related to index inclusion, such as the company’s expected addition to the Nasdaq Biotechnology Index, and conference presentations at healthcare and scientific meetings are also part of the regular news cycle.
Investors and followers of oncology drug development can use this page to track Immuneering’s disclosures about regulatory interactions with the FDA and EMA, combination trial agreements in non-small cell lung cancer, and intellectual property developments such as the granting of a U.S. composition of matter patent for atebimetinib. Bookmark this feed to monitor how Immuneering’s Deep Cyclic Inhibitor programs and corporate strategy evolve through official company communications.
Immuneering (Nasdaq: IMRX) announced positive initial Phase 2a data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. The initial results show:
- 40% initial response rate (2/5 patients)
- 80% initial disease control rate (4/5 patients)
- One complete response and one partial response observed
- All five patients continuing treatment
The combination has been well-tolerated at 240 mg QD, with additional patients now dosed at 320 mg QD. These results are consistent with preclinical data and exceed expectations for gemcitabine/nab-paclitaxel alone. Immuneering plans to continue clinical development, leveraging IMM-1-104's Fast Track designation for pancreatic cancer treatment.
Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place from September 4-6, 2024, at the Marriott Marquis in New York City.
Key executives, including CEO Ben Zeskind and CSO Brett Hall, will present in a fireside chat format on September 6 from 10:00 – 10:35 am ET. They will discuss Immuneering's pipeline, platform, and business strategy, focusing on their development of universal-RAS/RAF medicines for broad populations of cancer patients.
The presentation will be webcast live and archived on Immuneering's website in the Investor Relations section. This event provides an opportunity for investors to gain insights into the company's progress and future plans in the oncology field.
Immuneering (Nasdaq: IMRX) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. Enrollment progressing well in IMM-1-104 Phase 2a trial, with initial data from multiple arms expected in 2H 2024.
2. FDA Fast Track Designation granted for IMM-1-104 in first-line pancreatic cancer.
3. Preclinical data presented at AACR showing IMM-1-104 combined with chemotherapies yields deeper tumor growth inhibition in pancreatic cancer models.
4. Initial PK, PD, and safety data from IMM-6-415 Phase 1/2a trial expected in 2H 2024.
Financial highlights: Cash position of $59.7 million as of June 30, 2024. Q2 2024 R&D expenses were $10.7 million, G&A expenses were $4.3 million, and net loss was $14.1 million ($0.47 per share). Cash runway expected to fund operations into 2H 2025.
Immuneering (Nasdaq: IMRX) has received FDA Fast Track designation for IMM-1-104 as a first-line treatment for pancreatic ductal adenocarcinoma (PDAC). This follows the February 2024 Fast Track designation for second-line PDAC treatment. IMM-1-104 is designed to provide universal-RAS activity through Deep Cyclic Inhibition of the MAPK pathway with once-daily oral dosing.
The ongoing Phase 2a trial includes multiple arms evaluating IMM-1-104 in combination with chemotherapy for first-line PDAC patients, as monotherapy for first and second-line PDAC, and for RAS-mutant melanoma and lung cancer. Immuneering expects to share initial data from multiple arms in the second half of 2024.
Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, announced its participation in the Jefferies Global Healthcare Conference at the Marriott Marquis in New York City from June 5-6, 2024. The company's management team, including CEO Ben Zeskind and Chief Accounting Officer Mallory Morales, will discuss their pipeline, platform, and business strategy. The presentation is scheduled for June 5 from 4:30 – 4:55 pm ET in Track 2 and will be webcast live. The webcast will be archived in the Investor Relations section of Immuneering's website.
Immuneering (Nasdaq: IMRX) reported positive topline results from Phase 1 portion of the Phase 1/2a clinical trial of IMM-1-104 in RAS-Mutant Solid Tumors. First patient dosed in Phase 2a portion with initial data expected in 2024. Preclinical data combining IMM-1-104 with chemotherapies indicated improved tumor growth inhibition. Phase 1/2a trial of IMM-6-415 initiated for advanced solid tumors with RAF or RAS mutations. Fast Track designation received for IMM-1-104 in Pancreatic Cancer. Financially, cash position at $71.3 million as of March 31, 2024, with net loss of $14.3 million for Q1 2024.
Immuneering , a clinical-stage oncology company, is focused on developing universal-RAS/RAF medicines for cancer patients. The company is recognizing Melanoma Awareness Month by highlighting RAS mutant melanoma as the focus of its Phase 2a clinical study for IMM-1-104. Additionally, they are evaluating melanoma in their Phase 1/2a study of IMM-6-415. Immuneering expects to release initial data from multiple Phase 2a arms in 2024.
Summary not available.
Summary not available.
Summary not available.